Oro-dispersible Olanzapine (Wafer) Versus Conventional Oral Haloperidol or Diazepam Tablets for the Management of Acute Agitation in the Accident and Emergency Department - a Multicentre Randomised Clinical Trial

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olanzapine (Primary) ; Diazepam; Haloperidol
Indications Agitation
Focus Therapeutic Use

Most Recent Events

03 Nov 2020 Status changed from recruiting to discontinued. Reason the study was stopped:The study was terminated prematurely due to difficulties in patient recruitment and associatedpotential for selection bias.
25 Oct 2017 Status changed from not yet recruiting to recruiting.
15 Aug 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight